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ABSTRACT
Setting Children especially those <5 years of age 
exposed to pulmonary tuberculosis (TB) are at a high 
risk of severe TB disease and death. Isoniazid preventive 
therapy (IPT) has been shown to decrease disease 
progression by up to 90%. Kenya, a high TB burden 
country experiences numerous operational challenges 
that limit implementation of TB preventive services. IPT 
completion in child contacts is not routinely reported in 
Kenya.
Objective This study aims to review the child contact 
management (CCM) cascade and present IPT outcomes 
across 10 clinics in western Kenya.
Design A retrospective chart review of programmatic data 
of a TB Reach- funded active, clinic- based CCM strategy.
Results Of 553 child contacts screened, 231 (42%) were 
reported symptomatic. 74 (13%) of the child contacts were 
diagnosed with active TB disease. Of those eligible for IPT, 
427 (90%) initiated IPT according to TB REACH project 
data while 249 (58%) were recorded in the IPT register 
with 49 (11%) recorded as a transfer to other facilities. 
Of the 249 recorded in the IPT register, 205 (82%) were 
documented to complete therapy (48% of project initiation 
children).
Conclusion Our evaluation shows gaps in the 
routine CCM care cascade related to completeness 
of documentation that require further programmatic 
monitoring and evaluation to improve CCM outcomes.
INTRODUCTION
Worldwide, tuberculosis (TB) is one of the top 
10 causes of death and remains the leading 
infectious disease killer.1 Children—partic-
ularly those under 5 years of age—exposed 
to infectious pulmonary TB disease are at 
higher risk of severe disease and progression 
to death.2 It is estimated that 60%–80% of 
children with prolonged contact to a bacteri-
ologically positive index case become infected 
with TB.2 3
WHO recommends that children under 
age 5 or living with HIV of any age exposed 
to bacteriologically positive TB should be 
screened and started on appropriate treat-
ment—either isoniazid preventive therapy 
(IPT) if asymptomatic or active TB disease 
treatment.4 IPT decreases disease progres-
sion by approximately 90%.2 5 Operational 
challenges in the child contact manage-
ment (CCM) care cascade—identification, 
screening, treatment initiation and comple-
tion of therapy—continue to exist in high TB 
burden settings.6 7 Only 27% of eligible chil-
dren received IPT in 2018 globally.1
Kenya is one of 14 high TB burden 
countries with the highest burden of TB, 
multidrug- resistant TB and TB/HIV coin-
fection.8 Given the high burden of active TB 
disease, prioritising TB prevention is difficult 
with limited staff and resources. In 2018, only 
34% of child contacts <5 years initiated IPT.9 
Few African studies report varying degrees of 
IPT completion of therapy (COT) ranging 
from 12% to 76%.10–12 IPT COT outcomes 
among exposed child contacts have not been 
previously reported in Kenya.
At the Academic Model Providing Access 
to Healthcare (AMPATH) Partnership at Moi 
Teaching and Referral Hospital in Eldoret, 
Kenya, a previously described active, clinic- 
based child contact screening package 
funded through TB REACH Wave 2 was 
expanded across 10 sites in western Kenya 
in 2013 in an effort to improve CCM.13 Prior 
to the screening package, fewer than 1% of 
child contacts identified and documented 
by healthcare workers (HCWs) in a child 
Strengths and limitations of this study
 ► One of the first attempts to assess isoniazid pre-
ventive therapy completion of therapy outcomes in 
Kenya.
 ► Ten sites were visited to retrospectively collect pro-
grammatic data after a TB REACH initiative to ex-
pand child contact management.
 ► Data regarding index cases and child contacts 
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contact register underwent clinical review with treatment 
decisons.14 In the first year of the screening package, 86% 
of child contacts were brought in for evaluation and 89% 
of IPT- eligible child contacts were initiated on the recom-
mended 6 months of IPT.13
For this retrospective chart review of routine programme 
data, we visited 10 Wave 2 TB REACH treatment sites in 
western Kenya to retrospectively assess, for the first time, 
IPT and TB disease treatment outcomes for exposed 
child contacts as well as reasons leading to IPT deferral.
METHODS
Study design
We conducted a retrospective chart review of routine 
programme data of IPT and TB disease treatment 
outcomes in exposed child TB contacts under age 5 at 10 
sites across western Kenya. Our aim was to assess the final 
step of the CCM care cascade.
Setting
Kenya is a low- income and middle- income country with 
a TB incidence of 292 per 100 000 in 2018.9 The TB 
REACH active, clinic- based child screening package 
was implemented in TB clinics throughout western 
Kenya in 2013. The 10 TB clinics were located in urban 
(Eldoret, Webuye, Busia, Bungoma, Kakamega) and rural 
(Chulaimbo, Khunyangu, Kapenguria, Teso, Turbo) 
regions. As part of the TB REACH care programme, 
HCWs were asked to interview patients with active TB 
regarding child contacts and track the interview results in 
the CCM register. HCWs diagnosed TB in children based 
on the Kenyan National TB Programme (NTP) guide-
lines.15 In Kenya, the majority of TB in children is diag-
nosed clinically. This is due to the fact that facilities often 
lack personnel and supplies to conduct gastric aspirates.
Data collection and analysis
Data for the CCM programme were previously collected 
by TB clinic staff in the NTP child contact registers and 
project- specific child contact tracing forms. In 2016, 
members of the study team visited all 10 sites and collected 
data to assess IPT and TB disease treatment outcomes for 
child contacts screened between July 2013 and December 
2014. A child was considered initiating treatment if the 
project tracking form for that child so indicated. IPT and 
TB disease outcomes were then retrospectively collected 
Table 1 Demographics of exposed child TB contacts <5 years of age who were screened
TB disease No TB disease
Initially negative 




Total 74 466 6 7 553
Gender
  Male 31 (42%) 213 (46%) 3 2 249
  Female 42 (57%) 246 (53%) 3 5 296
  Data missing 1 (1%) 7 (2%) 0 0 8
Symptomatic for TB
  Yes 59 (80%) 167 (36%) 3 2 231
  No 15 (20%) 299 (64%) 3 5 322
X- ray result
  Normal 4 (5%) 322 (69%) 3 0 326
  Suggestive 67 (91%) 6 (1%) 2 0 73
  Data missing 3 (4%) 138 (30%) 1 6 148
Relationship to index case
  Parent 38 (51%) 276 (59%) 5 0 319
  Other 17 (23%) 118 (25%) 0 6
  Data missing 19 (26%) 72 (15%) 1 1 93
Child contact sleeps in the same room as index case
  Yes 42 (57%) 264 (57%) 4 5 315
  No 11 (15%) 69 (15%) 0 1 81
  Missing 21 (28%) 133 (29%) 2 1 157
Age
  Median 3 years 3 years 2.5 years 2 years
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from the local facility registers (child contact register, 
IPT and Treatment of disease registers). Treatment 
outcomes that were recorded from the registers included 
(1) completion—indication in register that the child 
completed IPT or TB treatment (2) deferral—indication 
in register that the child’s caregiver deferred treatment 
(3) transfer to another facility—indication in register or 
on TB REACH child contact tracing form that child trans-
ferred to another facility or (4) diagnosed with TB disease 
while on IPT. It is important to note that registers did not 
include detailed information about treatment follow- up 
visits such as adherence to medication or side effects.
Data were deidentified and entered into a password- 
protected Microsoft Excel database. Descriptive analyses 
were conducted in STATA version 14.2.430.
Patient and public involvement
Given that this was a retrospective analysis of a care 
programme, we did not have contact with any patients. 
Results from this analysis were disseminated with members 
of the Kenyan NTP.
RESULTS
Out of the 553 child contacts reviewed in the registers 
who were brought in for screening at the 10 TB clinics, 
249 (46%) were male and 319 (58%) were exposed to 
an index case who was their parent. A total of 545 of the 
child contacts had an age listed and median age was 3 
years. A total of 231 (42%) were symptomatic defined as 
the index case reporting that the child contact had one 
or more of the following—cough, weight loss/failure to 
thrive, fever or fatigue. Seventy- four (13%) of the child 
contacts were diagnosed with active TB disease (table 1).
Of the remaining child contacts without active TB 
disease, no clinical decision was reported for 7 (1%). 
Of the remaining 472, 427 (90%) were documented on 
the child contact tracing forms to have initiated IPT. 
According to personal communication with HCW staff, 
IPT initiation documented on the project forms was 
only done so if the child was sent home with an initial 
course of treatment. Only 249 (58%) were recorded in 
the IPT register. Forty- nine (11%) had a plan to transfer 
documented on the child contact tracing form. Of the 
249 recorded in the IPT register, 205 (82%) completed 
therapy; however, this is 48% completion if considering 
those who had documentation of IPT initiation initially 
on the child contact tracing forms (figure 1).
Of the 74 child contacts diagnosed with TB disease, 
100% had documentation of initiating TB treatment in 
the contact tracing form. Only 35 (47%) were found in 
the facility’s TB treatment register and 15 (20%) had 
an intent to transfer documented on the child contact 
tracing form. Of the 35 documented in the register, 34 
(97%) completed therapy; however, this is only 46% 
completion if considering those who had documentation 
of TB treatment initiation initially on the child contact 
tracing form (figure 1).
Forty- four child contacts deferred IPT: 23 (73%) chil-
dren initiated antibiotics for presumed upper respi-
ratory infection, 3 (10%) had TB previously, 4 (13%) 
had already received IPT at another facility and 1 (3%) 
deferred to await an X- ray that was not available at the 
time of screening. None of the 24 children who deferred 
for reasons other than previous treatment or had TB 
previously were documented to have ever returned to 
start their IPT.
Figure 1 Summary of child contact management outcomes in 10 TB clinics in western Kenya July 2013–December 2014. IPT, 
isoniazid preventive therapy; TB, tuberculosis. ⍏Percentage denominators represent the box immediately preceding; a6 returned 


















pen: first published as 10.1136/bm





4 Amisi JA, et al. BMJ Open 2021;11:e040993. doi:10.1136/bmjopen-2020-040993
Open access 
DISCUSSION
Our assessment of a CCM screening package in western 
Kenya reveals several interesting findings. The TB 
REACH- funded programme used child contact screening 
forms that documented IPT initiation in child contacts 
that otherwise did not appear in the national IPT regis-
ters. In fact, 90% of eligible child contacts were report-
edly initiated on IPT according to the programme’s 
forms, while only 58% were documented to have initiated 
IPT in the NTP registers. Personal communication with 
staff at the sites visited confirmed that child contacts were 
started on IPT if documented on the programme form. 
These rates of initiation are much higher than the most 
recent IPT initiation rate of 34% from 2018 and further 
suggests that an active, clinic- based CCM strategy may be 
an effective model for successful management of child TB 
contacts.
In the exploration of the fourth component of the 
CCM cascade—completion of therapy, we found that 48% 
of children documented to initiate IPT in our project 
child contact tracing forms had documentation of COT 
in the national databases. This suggests several potential 
systemic and logistical gaps. Once a child completed their 
clinical assessment and a treatment plan was determined, 
the following possible paths can occur: (1) the child may 
have started treatment at the clinic with documentation 
in a NTP register, (2) the child may have started treat-
ment but was not registered (and therefore not counted 
and COT cannot be tracked), (3) the child may have 
been transferred to another clinic with a lack of clarity 
about if and where registration occurred or (4) the HCW 
documented intent to initiate IPT and treatment was 
never initiated. Each of these scenarios determines the 
likelihood of documentation of COT.
Eleven percent of the children fell into the third cate-
gory above—stated transfer. We had no ability to verify the 
transfers, a problem also experienced by the Kenyan NTP 
in the setting of an evolving electronic reporting system. 
The 40% of children who were documented as initiating 
IPT by our project data capture, but not recorded or 
reported in the NTP registers, raises questions of what 
happened to the children—never started, started not 
recorded in register, or transferred? Given that HCWs 
reported that IPT initiation was only documented on 
project forms if the child was sent home on treatment, 
this suggests that children were started not recorded or 
transferred to another facility. Additionally, integration 
of grant- funded programmes into existing NTP data 
collection mechanisms is challenging and confusion can 
exist regarding the need for double entry of data versus 
entering data only in one location. It might be that a 
HCW did not complete the register after they completed 
the TB REACH child contact tracing form as this could 
seem like duplication. This is an important consideration 
for project teams to discuss with stakeholders and front- 
line HCWs. We also recommend that programmes assess 
data from both programmatic reporting tools and NTP 
registers periodically during the project. This would have 
allowed us to recognise the discrepancy in initiation and 
completion outcomes and investigate further in real time.
Of the children who programmatically were identified 
as starting on IPT and who entered the national regis-
tering system, 82% of the children identified within the 
NTP register as starting treatment had COT. This COT 
rate matches exactly the one found recently by Ngugi et 
al of IPT among children living with HIV at a national 
referral hospital in Kenya.16 These remarkably high COT 
rates also mirror the outcomes for Kenya for active TB 
disease. Methods for documentation of transfers for 
mobile populations are critical as well as training and 
supervision support around recording and reporting for 
programmes to understand fully what is happening to 
patient outcomes.
A major limitation to this evaluation is that we were not 
able to review data from surrounding facilities to cross-
check if child contacts were successfully transferred—this 
was due to the fact that the transfer facility was often not 
listed and the Kenyan electronic reporting system did not 
have complete IPT register data inputted. As reported 
in a systematic review regarding CCM implementation, 
there are numerous barriers throughout the CCM care 
cascade.17 Our study demonstrates that many additional 
steps exist beyond identification, screening, IPT initia-
tion and IPT completion (in this case—transfer of care). 
As more and more programmes and researchers track 
the CCM care cascade, the reported gaps are actually 
important opportunities to conduct a deeper dive into 
the problem.
Another limitation is that this retrospective chart review 
was limited in rigour given that we were collecting data 
available in registers and programme forms. Additionally, 
a selection bias may exist with the child contacts reviewed 
in the registers. Parents/caregivers who brought child 
contacts in may be worried about their children’s health, 
which could explain the large number of child contacts 
who were reportedly symptomatic.
A final programmatic gap identified in our study was 
the outcome of children for whom IPT was deferred. 
Only 25% of child contacts who deferred for a course of 
antibiotics were brought back for IPT initiation. Tracking 
of child contacts in low- income and middle- income coun-
tries like Kenya requires further programmatic guidelines 
and infrastructure . The current lack of support leads to 
HCWs’ ‘non- decision’ regarding IPT and a missed oppor-
tunity for disease prevention.
CONCLUSION
This is one of the first attempts to report IPT comple-
tion of therapy outcomes among child contacts <5 
years in Kenya. Our evaluation revealed potential gaps 
throughout the CCM care cascade—documentation of 
IPT initiation, transfer management and IPT deferral 
support. Our results also demonstrate the importance 
of integrating grant- funded monitoring and evaluation 
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mechanisms can lead to confusion. Further support 
for programmatic monitoring and evaluation as well as 
revised guidelines for transfers and deferrals could lead 
to continued improvement in CCM outcomes.
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